Skip to main content
British Heart Journal logoLink to British Heart Journal
. 1975 Jun;37(6):624–628. doi: 10.1136/hrt.37.6.624

Evaluation of haemodynamic effects of intravenous propranolol at low dosage (1 and 2 mg) in acute myocardial infarction.

B Letac, J Letournel
PMCID: PMC482846  PMID: 1148060

Abstract

The haemodynamic effects of intravenous propranolol at low dosage (1 and 2 mg) have been evaluated on 14 patients in the acute stage of myocardial infarction. The first 1 mg propranolol was not followed by any significant variation in the variables measured. After the second 1 mg propranolol, the heart rate, cardiac index, and stroke index decreased significantly but moderately. Changes in pulmonary wedge pressure were not significant. It is concluded that intravenous propranolol in the small dosage of 1 or 2 mg, at which antiarrhythmic effect is still produced, has only a negligible depressant myocardial effect.

Full text

PDF
624

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bay G., Lund-Larsen P., Lorentsen E., Sivertssen E. Haemodynamic effects of propranolol (Inderal) in acute myocardial infarction. Br Med J. 1967 Jan 21;1(5533):141–143. doi: 10.1136/bmj.1.5533.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Côte P., Harrison D. C., Basile J., Schroeder J. S. Hemodynamic interaction of procainamide and lidocaine after experimental myocardial infarction. Am J Cardiol. 1973 Dec;32(7):937–942. doi: 10.1016/s0002-9149(73)80161-4. [DOI] [PubMed] [Google Scholar]
  3. Ikram H. Propranolol in persistent ventricular fibrillation complicating acute myocardial infarction. Am Heart J. 1968 Jun;75(6):795–798. doi: 10.1016/0002-8703(68)90040-9. [DOI] [PubMed] [Google Scholar]
  4. Jewitt D. E., Reid D., Thomas M., Mercer C. J., Valori C., Shillingford J. P. Free noradrenaline and adrenaline excretion in relation to the development of cardiac arrhythmias and heart-failure in patients with acute myocardial infarction. Lancet. 1969 Mar 29;1(7596):635–641. doi: 10.1016/s0140-6736(69)92009-1. [DOI] [PubMed] [Google Scholar]
  5. Lewis C. M., Brink A. J. Beta adrenergic blockade. Hemodynamics and myocardial energy metabolism in patients with ischemic heart disease. Am J Cardiol. 1968 Jun;21(6):846–859. doi: 10.1016/0002-9149(68)90303-2. [DOI] [PubMed] [Google Scholar]
  6. Maroko P. R., Libby P., Braunwald E. Effect of pharmacologic agents on the function of the ischemic heart. Am J Cardiol. 1973 Dec;32(7):930–936. doi: 10.1016/s0002-9149(73)80160-2. [DOI] [PubMed] [Google Scholar]
  7. Rothfeld E. L., Lipowitz M., Zucker I. R., Parsonnet V., Bernstein A. Management of persistently recurring ventricular fibrillation with propranolol hydrochloride. JAMA. 1968 May 6;204(6):546–548. [PubMed] [Google Scholar]
  8. Stein P. D., Brooks H. L., Matson J. L., Hyland J. W. Effect of beta-adrenergic blockade on coronary blood flow. Cardiovasc Res. 1968 Jan;2(1):63–76. doi: 10.1093/cvr/2.1.63. [DOI] [PubMed] [Google Scholar]
  9. Wolfson S., Gorlin R. Cardiovascular pharmacology of propranolol in man. Circulation. 1969 Oct;40(4):501–511. doi: 10.1161/01.cir.40.4.501. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES